Programmable nucleases and methods of use
AssigneeMammoth Biosciences, Inc.
InventorsBenjamin Julius RAUCH, Aaron Deloughery, William Douglass Wright, David Paez-Espino
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods of use for Type V CRISPR/Cas proteins. Type V CRISPR/Cas proteins may be configured to bind and modify nucleic acids in a sequence specific manner.
Claims31
A composition comprising a programmable nuclease comprising an amino acid sequence, or a nucleic acid encoding the programmable nuclease, wherein the programmable nuclease is at least 70% identical to any one of SEQ ID NOs:
- 1-5;
- and an engineered guide nucleic acid, or a DNA molecule encoding the engineered guide nucleic acid, wherein the programmable nuclease binds to at least a portion of the engineered guide nucleic acid.
5-7. (canceled)
9-13. (canceled)
17-19. (canceled)
A composition comprising a programmable nuclease, or a nucleic acid encoding the programmable nuclease, and an engineered guide nucleic acid, or a DNA molecule encoding the engineered guide nucleic acid, wherein the programmable nuclease comprises:
- (i) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 1, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 255;
- (ii) an amino acid sequence that is at least 80% identical to any one of SEQ ID NOs:
- 2, 4, and 5, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 256;
- (iii) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 3, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 257;
- (iv) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 1, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 258;
- (v) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 2, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 259;
- (vi) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 3, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 260;
- (vii) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 4, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 261;
- or
- (viii) an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 5, and wherein the engineered guide nucleic acid comprises a nucleotide sequence that is at least 80% identical to SEQ ID NO:
- 262.
22-35. (canceled)
40-42. (canceled)
(canceled)
(canceled)
50-51. (canceled)
53-57. (canceled)
Dependencies are inferred from the claim text.